182 related articles for article (PubMed ID: 11688989)
1. Identification of dual cyclooxygenase-eicosanoid oxidoreductase inhibitors: NSAIDs that inhibit PG-LX reductase/LTB(4) dehydrogenase.
Clish CB; Sun YP; Serhan CN
Biochem Biophys Res Commun; 2001 Nov; 288(4):868-74. PubMed ID: 11688989
[TBL] [Abstract][Full Text] [Related]
2. Oxidoreductases in lipoxin A4 metabolic inactivation: a novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation.
Clish CB; Levy BD; Chiang N; Tai HH; Serhan CN
J Biol Chem; 2000 Aug; 275(33):25372-80. PubMed ID: 10837478
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin catabolic enzymes as tumor suppressors.
Tai HH
Cancer Metastasis Rev; 2011 Dec; 30(3-4):409-17. PubMed ID: 22020925
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of leukotriene B4 12-hydroxydehydrogenase/15-Oxo-prostaglandin 13-reductase catalytic mechanism and a possible Src homology 3 domain binding loop.
Hori T; Yokomizo T; Ago H; Sugahara M; Ueno G; Yamamoto M; Kumasaka T; Shimizu T; Miyano M
J Biol Chem; 2004 May; 279(21):22615-23. PubMed ID: 15007077
[TBL] [Abstract][Full Text] [Related]
5. 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line.
Quidville V; Segond N; Lausson S; Frenkian M; Cohen R; Jullienne A
Prostaglandins Other Lipid Mediat; 2006 Oct; 81(1-2):14-30. PubMed ID: 16997128
[TBL] [Abstract][Full Text] [Related]
6. Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase.
Wakimoto N; Wolf I; Yin D; O'Kelly J; Akagi T; Abramovitz L; Black KL; Tai HH; Koeffler HP
Cancer Res; 2008 Sep; 68(17):6978-86. PubMed ID: 18757412
[TBL] [Abstract][Full Text] [Related]
7. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells.
Chi X; Freeman BM; Tong M; Zhao Y; Tai HH
Arch Biochem Biophys; 2009 Jul; 487(2):139-45. PubMed ID: 19501039
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators.
Kowal-Bielecka O; Kowal K; Distler O; Rojewska J; Bodzenta-Lukaszyk A; Michel BA; Gay RE; Gay S; Sierakowski S
Arthritis Rheum; 2005 Dec; 52(12):3783-91. PubMed ID: 16320329
[TBL] [Abstract][Full Text] [Related]
9. An update on eicosanoids and inhibitors of cyclooxygenase enzyme systems.
Sharma S; Sharma SC
Indian J Exp Biol; 1997 Oct; 35(10):1025-31. PubMed ID: 9475035
[TBL] [Abstract][Full Text] [Related]
10. Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).
Tai HH; Chi X; Tong M
Prostaglandins Other Lipid Mediat; 2011 Nov; 96(1-4):37-40. PubMed ID: 21763448
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory potential of 2-styrylchromones regarding their interference with arachidonic acid metabolic pathways.
Gomes A; Fernandes E; Silva AM; Pinto DC; Santos CM; Cavaleiro JA; Lima JL
Biochem Pharmacol; 2009 Jul; 78(2):171-7. PubMed ID: 19464432
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of anti-configuration of indomethacin and leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase complex reveals the structural basis of broad spectrum indomethacin efficacy.
Hori T; Ishijima J; Yokomizo T; Ago H; Shimizu T; Miyano M
J Biochem; 2006 Sep; 140(3):457-66. PubMed ID: 16916844
[TBL] [Abstract][Full Text] [Related]
13. Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors.
Gray PA; Warner TD; Vojnovic I; Del Soldato P; Parikh A; Scadding GK; Mitchell JA
Br J Pharmacol; 2002 Dec; 137(7):1031-8. PubMed ID: 12429575
[TBL] [Abstract][Full Text] [Related]
14. Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization.
Castro MR; Lutz D; Edelman JL
Exp Eye Res; 2004 Aug; 79(2):275-85. PubMed ID: 15325574
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
16. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
Kashfi K; Rigas B
Biochem Pharmacol; 2005 Oct; 70(7):969-86. PubMed ID: 15949789
[TBL] [Abstract][Full Text] [Related]
17. Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.
Gobec S; Brozic P; Rizner TL
Bioorg Med Chem Lett; 2005 Dec; 15(23):5170-5. PubMed ID: 16183274
[TBL] [Abstract][Full Text] [Related]
18. Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells.
Krause MM; Brand MD; Krauss S; Meisel C; Vergin H; Burmester GR; Buttgereit F
Arthritis Rheum; 2003 May; 48(5):1438-44. PubMed ID: 12746918
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids.
Martel-Pelletier J; Mineau F; Fahmi H; Laufer S; Reboul P; Boileau C; Lavigne M; Pelletier JP
Arthritis Rheum; 2004 Dec; 50(12):3925-33. PubMed ID: 15593193
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents.
Cho H; Tai HH
Prostaglandins Leukot Essent Fatty Acids; 2002 Dec; 67(6):461-5. PubMed ID: 12468268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
